Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma overview
Gene therapy is under development for the treatment of R/R B-cell acute lymphocytic leukemia, non-Hodgkin lymphoma, mucosa-associated lymphoid tissue or malt-lymphoma, burkitt lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, diffuse large b-Cell lymphoma, relapsed and refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. It is a chimeric antigen receptor modified-T cell (CART). The therapeutic candidate acts by targeting cells expressing CD19 and CD22. It is administered through parenteral route.
Hebei Senlang Biotechnology overview
Hebei Senlang Biotechnology is a pharamaceutial and healthcare company which is involved in using bio technology for treatment of immune cells. The company is headquartered in Dongguan, Hebei, China.
For a complete picture of Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma’s drug-specific PTSR and LoA scores, buy the report here.